CN118460529A - 提高细胞基因组中同源定向修复(hdr)效率的方法 - Google Patents

提高细胞基因组中同源定向修复(hdr)效率的方法 Download PDF

Info

Publication number
CN118460529A
CN118460529A CN202410548057.9A CN202410548057A CN118460529A CN 118460529 A CN118460529 A CN 118460529A CN 202410548057 A CN202410548057 A CN 202410548057A CN 118460529 A CN118460529 A CN 118460529A
Authority
CN
China
Prior art keywords
hdr
cell
nuclease
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410548057.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·N·费德
郭齐
G·A·敏泰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61006349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN118460529(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN118460529A publication Critical patent/CN118460529A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202410548057.9A 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法 Pending CN118460529A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662437042P 2016-12-20 2016-12-20
US62/437,042 2016-12-20
PCT/US2017/067569 WO2018119060A1 (en) 2016-12-20 2017-12-20 Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome
CN201780086730.XA CN110300803B (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780086730.XA Division CN110300803B (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法

Publications (1)

Publication Number Publication Date
CN118460529A true CN118460529A (zh) 2024-08-09

Family

ID=61006349

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410548057.9A Pending CN118460529A (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法
CN201780086730.XA Active CN110300803B (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780086730.XA Active CN110300803B (zh) 2016-12-20 2017-12-20 提高细胞基因组中同源定向修复(hdr)效率的方法

Country Status (7)

Country Link
US (2) US20230193321A1 (cg-RX-API-DMAC7.html)
EP (2) EP3559230B1 (cg-RX-API-DMAC7.html)
JP (3) JP2020510443A (cg-RX-API-DMAC7.html)
KR (2) KR20230162134A (cg-RX-API-DMAC7.html)
CN (2) CN118460529A (cg-RX-API-DMAC7.html)
ES (1) ES2962711T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018119060A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN118460529A (zh) 2016-12-20 2024-08-09 百时美施贵宝公司 提高细胞基因组中同源定向修复(hdr)效率的方法
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US11952408B2 (en) * 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
EP3820503A4 (en) * 2018-07-13 2022-07-13 Allele Biotechnology & Pharmaceuticals, Inc. METHODS FOR HIGH SPECIFICITY GENOME EDITING
EP3994258A4 (en) 2019-07-03 2022-10-26 Integrated Dna Technologies, Inc. IDENTIFICATION, CHARACTERIZATION AND QUANTIFICATION OF DOUBLE-STRAND DNA BREAK REPAIR INTRODUCED BY CRISPR
CA3154370A1 (en) * 2019-10-24 2021-04-29 Jessica WOODLEY Modified double-stranded donor templates
CN111549052A (zh) * 2020-05-07 2020-08-18 西南大学 一种真核生物CRISPR/Cas全基因组编辑载体文库及构建方法
US20230257768A1 (en) * 2020-06-12 2023-08-17 National Institute Of Advanced Industrial Science And Technology Poultry cell in which a gene encoding a protein of interest is knocked-in at egg white protein gene, and method for producing said poultry cell
CN111944847A (zh) * 2020-08-28 2020-11-17 西北农林科技大学 一套等位基因高效替换系统及其建立方法
CN113416730B (zh) * 2021-07-07 2023-04-04 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种降低细胞因基因编辑产生的大片段删除突变的方法
GB202117455D0 (en) * 2021-12-02 2022-01-19 Academisch Ziekenhuis Leiden Method of editing nucleic acid

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
CA2186118C (en) 1994-03-23 2010-10-19 Richard W. Hanson Compacted nucleic acids and their delivery to cells
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US8772008B2 (en) * 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2012012738A1 (en) * 2010-07-23 2012-01-26 Sigma-Aldrich Co., Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
EP4019635A1 (en) 2015-03-25 2022-06-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
EP3274453B1 (en) * 2015-03-26 2021-01-27 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
CN107787367B (zh) 2015-04-06 2021-10-26 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
CN105734032A (zh) * 2016-03-25 2016-07-06 扬州大学 一种山羊blg基因定点敲除修饰系统及应用
CN118460529A (zh) 2016-12-20 2024-08-09 百时美施贵宝公司 提高细胞基因组中同源定向修复(hdr)效率的方法

Also Published As

Publication number Publication date
CN110300803B (zh) 2024-05-14
EP4286523A3 (en) 2024-03-20
KR20190095412A (ko) 2019-08-14
EP3559230A1 (en) 2019-10-30
EP4286523A2 (en) 2023-12-06
ES2962711T3 (es) 2024-03-20
EP3559230B1 (en) 2023-09-06
US20230193321A1 (en) 2023-06-22
JP2026012785A (ja) 2026-01-27
US20260132427A1 (en) 2026-05-14
JP2024009934A (ja) 2024-01-23
KR20230162134A (ko) 2023-11-28
JP2020510443A (ja) 2020-04-09
WO2018119060A1 (en) 2018-06-28
CN110300803A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
CN110300803B (zh) 提高细胞基因组中同源定向修复(hdr)效率的方法
JP7419328B2 (ja) ゲノムエンジニアリング
EP3074515B1 (en) Somatic haploid human cell line
US20190330603A1 (en) Crispr-cas system, materials and methods
JP2017536811A (ja) 多能性細胞の樹立又は維持のための方法及び組成物
BR112017016080B1 (pt) Polinucleotídeo crispr da classe 2 único, sistema crispr da classe 2 e método in vitro de modificação de uma molécula de ácido nucleico alvo em um organismo não-humano, ou em uma célula
US11459586B2 (en) Methods for increasing efficiency of nuclease-mediated gene editing in stem cells
Chang A Programable CRISPR System to Methylate and Demethylate N6-Methlyadenosine on Specific Transcripts in Mammalian Cells
NZ754904A (en) Genome engineering
NZ754904B2 (en) Genome engineering
BR122019001480B1 (pt) Conjunto de dois polinucleotídeos crispr de classe 2, sistema crispr de classe 2, métodos in vitro de modificação de uma molécula de ácido nucleico alvo e para modular a transcrição de pelo menos um gene na molécula de ácido nucleico alvo
NZ754903B2 (en) Genome engineering

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination